Axentis Pharma acquires cystic fibrosis patent rights from Austrian firm: related news

Axentis Pharma acquires cystic fibrosis patent rights from Austrian firm

The rights to key patents for an innovative screening tool for treatments for cystic fibrosis were transferred to Swiss biotech company Axentis Pharma AG. The company has acquired the rights from an Austrian firm that has made a vital contribution to the development of new approaches to treating the disease.

Axentis Pharma Gains Patents from BioDevelops Pharma to Further Cystic Fibrosis Program

Axentis Pharma has obtained patents from BioDevelops Pharma related to a cystic fibrosis treatment. The acquired therapeutic approach enables proteins, which get destroyed in spite of have some functionality, to escape.

DP6946 Patent Thickets and the Market for Innovation: Evidence from Settlement of Patent Disputes

We study how fragmentation of patent rights (‘patent thickets’) and the formation of the Court of Appeal for the Federal Circuit (CAFC) affected the duration of patent disputes, and thus the speed of technology diffusion through licensing. We develop a model of patent litigation which predicts faster settlement agreements when patent rights are fragmented and when there is less uncertainty about court outcomes, as was associated with the ‘pro-patent shift’ of CAFC. The model also predicts that the impact of fragmentation on settlement duration should be smaller under CAFC. We confirm these predictions empirically using a dataset that covers nearly all patent suits in U.S. federal district courts during the period 1975-2000. Finally, we analyze how fragmentation affects total settlement delay, taking into account both reduction in duration

Warner Chilcott Announces New Information in USPTO Reexamination of TACLONEX Patent

announced today that LEO Pharma A/S ("LEO Pharma") has received a Right of Appeal Notice from the U.S. Patent and Trademark Office (the "USPTO"). In September 2006, the USPTO ordered a reexamination of LEO Pharma's US Patent No. 6,753,013 (the "013 Patent") in response to a request made by Galderma R&D. The 013 Patent covers TACLONEX(R) products and certain of LEO Pharma's products in development. Warner Chilcott markets and sells TACLONEX(R) products in the United States under a license agreement with LEO Pharma and has license rights to certain products in development.

Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent

ST. DAVID'S, Bermuda, July 24, 2008 /PRNewswire-FirstCall/ -- Warner Chilcott Limited announced today that LEO Pharma A/S ("LEO Pharma") has received a Right of Appeal Notice from the U.S. Patent and Trademark Office (the "USPTO"). In September 2006, the USPTO ordered a reexamination of LEO Pharma's US Patent No. 6,753,013 (the "013 Patent") in response to a request made by Galderma R&D. The 013 Patent covers TACLONEX(R) products and certain of LEO Pharma's products in development. Warner Chilcott markets and sells TACLONEX(R) products in the United States under a license agreement with LEO Pharma and has license rights to certain products in development.

Supreme Court strengthens patent exhaustion doctrine

The United States Supreme Court has unanimously held in Quanta Computer, Inc. v. LG Electronics, Inc. that the patent law cannot be used to control the subsequent use or disposition of a product "that substantially embodies a patent" once the product has been sold with authority of the patent owner. "The authorized sale of an article that substantially embodies a patent exhausts the patent holder's rights and prevents the patent holder from invoking the patent law to control post-sale use of the article." Patent exhaustion applies whether the patents are directed to products or methods. "Our precedents do not differentiate transactions involving embodiments of patented methods or processes from those involving patented apparatuses or materials.

Drugs industry protecting 'morally unacceptable' patent system

Add our medical news to digg - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to NewsVine - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Fark - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Furl - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Shadows - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to YahooMyWeb - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Reddit -Drugs industry protecting 'morally unacceptable' patent system Add our medical news to StumbleUpon - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Facebook - Drugs industry protecting 'morally unaccep

Health Discovery Corporation Inks Agreement with Patent Profit International for Monetization of Patent Portfolio

Health Discovery Corporation (HDVY), a leader in support vector machine (SVM) based molecular diagnostic and prognostic test development today announced the signing of an Agreement with Patent Profit International (PPI), a Silicon Valley-based patent brokerage firm, with the goal of exploiting the full monetization potential of HDC's extensive pioneering patent portfolio. Under the agreement, PPI will market HDC's patent portfolio, which includes exclusive rights to SVM techniques and applications that reach far beyond biomarker discovery and the Healthcare Field, to prospective buyers/licensees in a wide range of technologies, including, but not limited to, information technology such as Internet browsers and search engines, spam mail detection, oil exploration, homeland security, and the automotive industry.

Health Discovery Corporation Inks Agreement with Patent Profit International for Monetization of Patent Portfolio

Health Discovery Corporation (OTCBB:HDVY), a leader in support vector machine (SVM) based molecular diagnostic and prognostic test development today announced the signing of an Agreement with Patent Profit International (PPI), a Silicon Valley-based patent brokerage firm, with the goal of exploiting the full monetization potential of HDC's extensive pioneering patent portfolio. Under the agreement, PPI will market HDC's patent portfolio, which includes exclusive rights to SVM techniques and applications that reach far beyond biomarker discovery and the Healthcare Field, to prospective buyers/licensees in a wide range of technologies, including, but not limited to, information technology such as Internet browsers and search engines, spam mail detection, oil exploration, homeland security, and the automotive industry.

Health Discovery Corporation Inks Agreement with Patent Profit International for Monetization of Patent Portfolio

SAVANNAH, Ga. - (Business Wire) Health Discovery Corporation (OTCBB:HDVY), a leader in support vector machine (SVM) based molecular diagnostic and prognostic test development today announced the signing of an Agreement with Patent Profit International (PPI), a Silicon Valley-based patent brokerage firm, with the goal of exploiting the full monetization potential of HDC's extensive pioneering patent portfolio. Under the agreement, PPI will market HDC's patent portfolio, which includes exclusive rights to SVM techniques and applications that reach far beyond biomarker discovery and the Healthcare Field, to prospective buyers/licensees in a wide range of technologies, including, but not limited to, information technology such as Internet browsers and search engines, spam mail detection, oil exploration, homeland security, and the automotive

Health Discovery Corporation Inks Agreement with Patent Profit International for Monetization of Patent Portfolio

SAVANNAH, Ga. (Business Wire) -- Health Discovery Corporation (OTCBB:HDVY), a leader in support vector machine (SVM) based molecular diagnostic and prognostic test development today announced the signing of an Agreement with Patent Profit International (PPI), a Silicon Valley-based patent brokerage firm, with the goal of exploiting the full monetization potential of HDC's extensive pioneering patent portfolio. Under the agreement, PPI will market HDC's patent portfolio, which includes exclusive rights to SVM techniques and applications that reach far beyond biomarker discovery and the Healthcare Field, to prospective buyers/licensees in a wide range of technologies, including, but not limited to, information technology such as Internet browsers and search engines, spam mail detection, oil exploration, homeland security, and the automotive

Tech Companies Team Up To Buy Up Patents To Keep Them Away From Others

Google, Verizon, HP, Cisco and some others are apparently teaming up to put money towards buying patents to keep them out of the hands of patent hoarders who would turn around and sue them. This isn't a new concept, and has been tried before -- and it didn't help much. The problem is that many of the worst patent suits aren't from "known" patents, but someone claiming a patent on some minor feature that everyone thought was obvious. Also, this type of action only encourages more bad patent activities by adding another buyer to the market. Now, questionable patent holders will recognize that they can also just sell to this patent pool, rather than selling to some patent hoarding firm. This is one of those ideas that sounds good on paper, but will have little to no effect on slowing down or stopping bad patent lawsuits, and may actually enc

JPEG Patent's Single Claim Rejected (And Smacked Down For Good Measure)

We've been covering the ongoing saga of an old patent we've referred to as the "JPEG Patent." This actually isn't the first patent we've called the JPEG Patent, because multiple people claimed to hold patents over the technology that goes into a JPEG image. But, this one was rather special. The patent had been used, repeatedly, by lawyer Ray Niro, against a wide range of opponents, including a patent system critic. The end result was a drawn out review process where all of the original claims were rejected, but a single new claim was added to the patent, which Niro insisted covered JPEGs on a website.

Silence Therapeutics Announces Successful Opposition of Glover Patent

a leading European RNA interference (RNAi) focused biotechnology company, announced today the successful opposition of a fundamental Alnylam Pharmaceuticals, Inc. European patent resulting in the patent being revoked in its entirety. The Opposition Division of the European Patent Office, following a three day hearing, announced its decision to revoke European Patent EP 1 230 375, exclusively licensed to Alnylam Pharmaceuticals from Cancer Research Technology, Ltd (UK). The Patent, commonly referred to as the "Glover" patent, broadly relates to medicaments comprising an RNA interference mediating RNA molecule. Opposition briefs to the Glover patent had been filed by Silence Therapeutics AG, Sanofi-Aventis Deutschland GmbH, Quark Biotech, Inc.

PATENT REFORM IS NOT NECESSARY

Virtually all of the problems of the U.S. Patent system, including the high cost of obtaining a patent can be attributed to examiners issuing improper "bogus" rejections. While I know this is tue from my experience as a patent examiner, I performed a survey {using the PTO's Patent Application Information Retrieval (PAIR) system} of the 50 most recently issued patents classified in Class 435, Chemistry: Molecular Biology and Microbiology. In 76% of these patents, the examiner indicated in the first Office action that there was no allowable subject matter, i.e. none of the claims are patentable. Are the abilities of patent attorneys so low that over 75% of patent applications as filed do not contain at least one allowable claim? Or are the examiners writing "bogus" rejections? The answer is the latter.

Acacia Research unit acquires rights to patent for content management technology - Quick Facts

Acacia Research (ACTG) acquires rights to patent relating to enterprise content management technology

Acacia Subsidiary Acquires Rights to Patent for Enterprise Content Management Technology

Acacia Research Corporation (Nasdaq:ACTG) announced today that its subsidiary, Acacia Patent Acquisition LLC, has acquired rights to a patent relating to enterprise content management technology.

Non-Disruptive Backups and Migrations Enhances European Patent Protection and Management

The European Patent Office grants European patents. The EPO carries out searches and substantive examinations on a steadily rising number of European patent applications and international applications filed under the Patent Cooperation Treaty. The European Patent Office (EPO) needed to support up to 60 million patents documents and 800,000 patents within a high availability and ultra resilient DB2 environment. The European Patent Office deployed BMC DB2 solutions to more effectively support its customers and the management of its patent applications.

German Court Rules Qualcomm GSM Patent Claim Against Nokia Invalid

The German Federal Patent Court ruled today that Qualcomm’s GSM patent case against Nokia (NYSE: NOK) is invalid, Reuters reports. This is the third court to conclude that the American chipmaker’s patent claims against Nokia are “without merit,� said the Finnish handset maker. The United Kingdom High Court, and the U.S. International Trade Commission have also ruled that Qualcomm’s GSM patent claims against Nokia to be invalid. The two will meet again in German court in October, when a second Qualcomm (NSDQ: QCOM) patent case will be heard. The news comes on the same day that Qualcomm and Nokia are to meet in a Deleware Court over its ongoing patent dispute.

Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)

announced today the issuance of U.S. Patent No. 7,410,978 (the "'978 patent"), entitled "Once Daily Dosage Forms of Trospium," which is licensed exclusively to the Company by the patent's assignee, Supernus Pharmaceuticals, Inc. The '978 patent covers the Company's approved product, SANCTURA XR(TM), a once-a-day formulation of trospium chloride which is indicated for the treatment of symptoms of an overactive bladder. Based on calculations made by the United States Patent and Trademark Office, the term of the '978 patent is twenty years plus 89 days from its filing date of November 4, 2004, or February 1, 2025. In September 2007, the Company entered into an agreement with Allergan, Inc. by which the Company granted Allergan an exclusive sublicense to market SANCTURA XR in the United States.

Rim Semiconductor Files Patent Application

July 10, 2008 (FinancialWire) Rim Semiconductor Co. (OTCBB: RSMI) (Current Market Cap. US$356,698.00) filed a non-provisional patent application on its RQAM technology. Rim Semi s Cupria transport processor is based on this RQAM technology, and is able to drive data traffic at more than 40 megabits per second. Existing technologies are able to drive data 15 mbps at this distance on this wire type. The patent, titled Amplitude Modulation Decoder, was filed as a non-provisional patent with the United States Patent and Trademark Office. It was also filed under the Patent Cooperation Treaty. This protects Rim Semi s intellectual property rights across a wide geography. Other companies trading in Rim Semi s industry include ABB Ltd. (NYSE: ABB), Eaton Corp.

Vaccine Containing Tumor Antigen Reduces Colon Cancer Spread in Mice Axentis Pharma Gains Patents from BioDevelops Pharma to Further Cystic Fibrosis Program Articles Most Viewed Most Emailed Top Searches Optimizing Utilization of Biomarkers Meth

Scientists at the Kimmel Cancer Center at Jefferson Medical College have found a way to immunize mice against the development of metastatic disease. Their approach is based on the fact that the intestines have a separate immune system from the rest of the body. The researchers were able to show that mice immunized with an intestinal protein developed fewer lung and liver metastases after injection with colon cancer cells than did control animals.

Search took 0.27 seconds.